Bone Biologics (BBLG) Other Working Capital Changes (2014 - 2025)
Bone Biologics (BBLG) posted quarterly Other Working Capital Changes of -$71347.0 for Q3 2025, up 26.8% year-over-year from -$56266.5 in Q3 2024, and down 32.72% quarter-over-quarter from -$53757.0 in Q2 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Other Working Capital Changes (2014 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Other Working Capital Changes for 11 consecutive years, with -$71347.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Working Capital Changes rose 26.8% year-over-year to -$71347.0; the TTM figure through Sep 2025 stood at -$32221.0 (down 118.98% YoY), while the FY2024 annual figure was -$104171.0, down 2052.6% from the prior year.
- Other Working Capital Changes declined to -$71347.0 in Q3 2025 per BBLG's latest filing, from -$53757.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $438502.0 in Q4 2023 and bottomed at -$361491.0 in Q1 2023.
- Historically, Other Working Capital Changes has averaged $5428.6 across 4 years, with a median of -$71347.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes surged 126.49% — and 2024, when it sank 463.44%.
- Bone Biologics' Other Working Capital Changes stood at $235281.0 in 2022, then jumped by 86.37% to $438502.0 in 2023, then plunged by 62.48% to $164529.0 in 2024, then slumped by 143.36% to -$71347.0 in 2025.
- Business Quant data shows BBLG's Other Working Capital Changes at -$71347.0 in Q3 2025, -$53757.0 in Q2 2025, and -$71646.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -71,347.00 |
| Sep 30, 2025 | -71,347.00 |
| Jun 30, 2025 | -53,757.00 |
| Jun 30, 2025 | -53,757.00 |
| Mar 31, 2025 | -71,646.00 |
| Mar 31, 2025 | -71,646.00 |
| Dec 31, 2024 | 164,529.00 |
| Dec 31, 2024 | 164,529.00 |
| Sep 30, 2024 | -97,471.00 |
| Sep 30, 2024 | -97,471.00 |
| Jun 30, 2024 | -71,975.00 |
| Jun 30, 2024 | -71,975.00 |
| Mar 31, 2024 | -99,254.00 |
| Mar 31, 2024 | -99,254.00 |
| Dec 31, 2023 | 438,502.00 |
| Dec 31, 2023 | 438,502.00 |
| Sep 30, 2023 | -91,480.00 |
| Sep 30, 2023 | -91,480.00 |
| Jun 30, 2023 | 19,804.00 |
| Jun 30, 2023 | 19,804.00 |